Showing results (141-150 of 164) with videos related to

Sort By:
Pageof 17
British Journal of Cancer|December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinomaMichael Cecchini, James M Cleary, Yu Shyr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2021
Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)Evanthia T Roussos Torres, Christine Rafie, Chenguang Wang, et al.
The Lancet. Oncology|November 18, 2021
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion studyNehal J Lakhani, Laura Q M Chow, Justin F Gainor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 TrialPatrick Schöffski, Roberta Sanfilippo, Javier Martín-Broto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2013
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group studyStephen I Shibata, Vincent Chung, Timothy W Synold, et al.
Cancer Immunology, Immunotherapy : CII|April 4, 2023
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumorsJohanna Bendell, Patricia LoRusso, Michael Overman, et al.
JCO Clinical Cancer Informatics|January 9, 2026
Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence-Driven System for Semiautomated Patient Prescreening in Cancer Clinical TrialsGuannan Gong, Jessica Liu, Sameer Pandya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid TumorsKyung Hae Jung, Patricia LoRusso, Howard Burris, et al.
JAMA Oncology|September 28, 2023
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled TrialTae Won Kim, Philippe L Bedard, Patricia LoRusso, et al.
The Lancet. Oncology|September 8, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyD Ross Camidge, Yung-Jue Bang, Eunice L Kwak, et al.
Pageof 17